The week of May 13 in review, featuring stories and videos on cabozantinib in medullary thyroid cancer, biomarkers in prostate cancer, and SAR302503 in myelofibrosis.
Radium RA 223 dichloride (Xofigo) has been approved by the FDA for the treatment of symptomatic metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones but not to any other organs.Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses a phase I/IIa study looking at radium-223 with docetaxel in patients with bone metastasis from castration-resistant prostate cancer.In advance of the 2013 ASCO annual meeting,Targeted Therapy Newsspoke with this year’s chair of the Scientific Program Committee, Douglas Yee, MD, about key presentations and sessions that attendees can expect.ASCO highlighted studies on treatment with ipilimumab and nivolumab in advanced melanoma, radiation in NSCLC, and idelalisib in chronic lymphocytic leukemia.Abstracts published in the Annual Meeting Proceedings Part I featuring late-stage data on ibrutinib, eribulin, regorafenib, sipuleucel-T, lambrolizumab, palbociclib, and more.Monica Fradkin, RN, BSN, MPH, OCN, Oncology Nursing Education Coordinator, Yale School of Nursing, Smilow Cancer Hospital at Yale-New Haven, discusses treating patients with chemotherapy and biotherapy.Follicular lymphoma is characterized by repeated treatment responses and then relapses, and researchers will need to generate a growing list of drug choices to keep pace with patients’ needs.Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, describes intratumoral heterogeneity in patients with breast cancer.A new study suggests that even tumor cells with a common genetic background can display functional heterogeneity.
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen